![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, July 24, 2018 11:27:59 AM
For instance, he described their other areas or research as "associated with Glaucoma", making it sound like NMUS is a one-trick pony on glaucoma.
Past PR's seem to strongly indicate that the other indications they are pursuing are actually large and separate markets, such as "NB2111 displayed abuse-deterrent activity in a validated animal model of oxycontin addiction." or “We have been able to demonstrate that NB2111 was able to deliver analgesia comparable to morphine, which has been implicated in the current global opioid abuse epidemic." These quotes from past PR's actually indicate much bigger target markets such as: The global pain market, estimated to be more than $30 billion (Transparency Market Research, 2016), is in need of alternatives to opioid-based medicines," commented Brian Murphy, MD, MBA, the Nemus CEO and Chief Medical Officer.
He doesn't even do a very good job of describing why a "prodrug" formulation is so much better than raw medical marijuana other than to say "patented", I would have appreciated if he got more detailed about the ability to isolate the medicinal effects of the hundreds of different individual compounds and concentrate those constituents for a more efficacious treatment than could be provided by raw plant material, or concentrates.
"Our houses are such unwieldy property that we are often imprisoned rather than housed in them." - Henry David Thoreau, Walden: Economy, 1854
Recent SKYE News
- Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND™ Phase 2 Trial of Nimacimab for Obesity • GlobeNewswire Inc. • 07/24/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 01:27:39 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/20/2024 04:15:09 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/17/2024 08:27:44 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/10/2024 08:19:14 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/10/2024 08:17:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:02:13 PM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM